Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
11.67
+0.36 (3.14%)
Nov 21, 2024, 12:59 PM EST - Market open
Stoke Therapeutics Employees
Stoke Therapeutics had 110 employees as of December 31, 2023. The number of employees decreased by 7 or -5.98% compared to the previous year.
Employees
110
Change (1Y)
-7
Growth (1Y)
-5.98%
Revenue / Employee
$152,209
Profits / Employee
-$958,700
Market Cap
617.86M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| agilon health | 1,117 |
| Definitive Healthcare | 950 |
| Exscientia | 483 |
| Phathom Pharmaceuticals | 452 |
| Ironwood Pharmaceuticals | 267 |
| Entrada Therapeutics | 159 |
| Tourmaline Bio | 44 |
| Oculis Holding AG | 36 |
STOK News
- 16 days ago - Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates - Business Wire
- 2 months ago - Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome - Business Wire
- 2 months ago - Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome - Seeking Alpha
- 2 months ago - Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer - Business Wire
- 2 months ago - Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire
- 2 months ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in September - Business Wire
- 3 months ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 3 months ago - Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates - Business Wire